Monday, January 18, 2021
Home Latest News Curigin builds Bi-Specific, Sh-RNA oncolytic virus platform

[MIK Hot Spot_KHIDI] Curigin builds Bi-Specific, Sh-RNA oncolytic virus platform

[vsw id=”uV2zm4dPoHs” source=”youtube” width=”600″ height=”337″ autoplay=”no”]

Curigin participated in the MIK Hot Spot (Made in Korea Online Exhibition) KHIDI and introduced the Bi-Specific, Sh-RNA oncolytic virus platform with high hopes of meeting buyers and investors.

Q. Please introduce your company.

Hello, I am Lee Wan, the CEO of Curigin. I am currently a professor at Wonkwang University School of Dentistry. I am diagnosing diseases and researching diseases. I studied cancer treatment drugs and basic science at USC in the US. Now, I am the CEO of Curigin.

Curigin is a venture company based on multi-target RNAi technology and anti-cancer virus platform with unique cancer specificity. We are a gene therapy company trying to reach more fundamental treatment of cancer and various diseases.

Q. What are the different characteristics of Curigin?

We would like to introduce the advantages of Curigin with 3S called Smart Safe Speed. First, cancer is expressed by a special gene, and there is a smart system that finds these genes using big data and our own algorithm.

Normally, cancer is associated with two or more genes, and our bioinformatics team can find the sequences of two genes that can be reverse complementarily assembled for each disease, making Bi-Specific and Sh-RNA suitable for each disease.

Second, we are producing safe anti-cancer viruses by mounting a cancer-specific promoter that does not work on normal cells but only on cancer cells.

Lastly, as long as the Bi-Specific and Sh-RNA oncolytic virus platforms are built and Sh-RNAs are developed for each disease, installing them in the cassette type will produce a proper drug, thus significantly reducing time from development to production. We have even acquired the technology to administer these treatment drugs not only topically but also systemically.

Q. What roles do the members have?

Our general director who was formerly our medical school professor has so much experience in patients and clinical trials. He will play an important role in our clinical trials. Also, team leaders with master’s and doctorate degrees in genetic engineering and experience in experiments related to this are leading various experiments. Currently, 18 employees are divided in working on drug design production PoC efficacy evaluation. We have three executives in the clinical trial, so we can develop the treatment drugs that are needed to the clinical trials.

Q. What are your future plans?

Currently, contracts have been signed with CMOs equipped with GMP facilities at domestic and overseas facilities to begin development of anti-cancer viruses loaded with Sh-RNA. And, we are planning to complete the production of the virus with the pipeline for bladder and prostate cancer by this July. Accordingly, we aim to conduct preclinical trial by the end of September.

The products and services of the major companies of KHIDI Health Industry Startup Innovation Center in the MIK Hot Spot (Made in Korea Online Exhibition) will also be displayed in BIO KOREA 2020. Asia’s biggest bio convention BIO KOREA 2020 co-organized by KHIDI and Chungbuk Province and sponsored by MOHW will be open online due to the COVID-29 pandemic on May 18-23. Virtual exhibition halls, conference, and business forums will be operated, and the companies will be promoting their competitiveness. Also, with video meetings, businesses between overseas speakers, buyers, and domestic and foreign participating companies will be made. To date, more than 160 companies have applied for the virtual exhibition booth at BIO KOREA 2020. Companies wishing to participate can apply through the web page or email by Apr. 30.

The global news network AVING News has begun holding the MIK Hot Spot (Made in Korea Online Exhibition) to help small and medium-sized companies enter the market and attract investment 365 days a year. AVING News has been running online exhibitions since 2005 and had 975 online exhibitions so far. Its YouTube online exhibition has placed itself as Korea’s largest online exhibition hall that opens with 19,000 videos (booths) with more than 800,000 visits per month which means more than 10 million visits per year. The MIK Hot Spot online exhibition is scheduled to be held regularly according to the field, target market, and participating institutions, and it will be presented as a new type of online business by transforming the know-hows and values of the participating companies according to the trend. Companies that want to participate can apply and apply through the marketing support projects from supporting institutions in the local governments. Refer to the institutions for more information.

→ Go to MIK Hot Spot (Made in Korea Online Exhibition) special page

→ Go to MIK Hot Spot (Made in Korea Online Exhibition) information page

- Advertisment -

Most Popular

Recent Comments